Clinical Trials

Dutch regulators have signed off on AXIM Biotechnologies’ clinical trial plans for a chewing gum that offers controlled release of cannabinoids to treat multiple sclerosis patients’ pain and spasticity. The Dutch Medicines Evaluation Board’s sign-off on MedChew Rx means AXIM can start trials. A leader in cannabinoid research, New York-based AXIM is developing 16 cannabinoid-based pharmaceutical, nutrition and cosmetic […]

by

Treatment with a pharmaceutical formulation of cannabidiol alongside other anti-epilepsy treatments helped to reduce the number of drop seizures in people with Lennox-Gastaut syndrome… Treatment with a pharmaceutical formulation of cannabidiol alongside other anti-epilepsy treatments helped to reduce the number of drop seizures – seizures which involve sudden falls due to loss of muscle tone […]

by

Treatment with a pharmaceutical formulation of cannabidiol alongside other anti-epilepsy treatments helped to reduce the number of drop seizures in people with Lennox-Gastaut syndrome… Treatment with a pharmaceutical formulation of cannabidiol alongside other anti-epilepsy treatments helped to reduce the number of drop seizures – seizures which involve sudden falls due to loss of muscle tone […]

by

Treatment with a pharmaceutical formulation of cannabidiol alongside other anti-epilepsy treatments helped to reduce the number of drop seizures in people with Lennox-Gastaut syndrome… Treatment with a pharmaceutical formulation of cannabidiol alongside other anti-epilepsy treatments helped to reduce the number of drop seizures – seizures which involve sudden falls due to loss of muscle tone […]

by

A key cannabis compound helped to reduce the number of drop seizures in patients with a severe form of epilepsy, newly published results of a clinical trial suggest. The study, published Wednesday in The Lancet, suggests that cannabidiol, alongside other anti-epilepsy treatments, reduced drop seizures in those who suffer from Lennox-Gastaut syndrome. Drop seizures involve […]

by

A key cannabis compound helped to reduce the number of drop seizures in patients with a severe form of epilepsy, newly published results of a clinical trial suggest. The study, published Wednesday in The Lancet, suggests that cannabidiol, alongside other anti-epilepsy treatments, reduced drop seizures in those who suffer from Lennox-Gastaut syndrome. Drop seizures involve […]

by

A key cannabis compound helped to reduce the number of drop seizures in patients with a severe form of epilepsy, newly published results of a clinical trial suggest. The study, published Wednesday in The Lancet, suggests that cannabidiol, alongside other anti-epilepsy treatments, reduced drop seizures in those who suffer from Lennox-Gastaut syndrome. Drop seizures involve […]

by

An inside look at Prime Minister Justin Trudeau’s luxurious Davos hotel, Canadian journalists left out as Trudeau meets with Israeli prime minister, and how cannabis could help prevent seizures among patients with a severe form of epilepsy. 1. Davos digs Prime Minister Justin Trudeau is in Davos, Switzerland, where he and several ministers are working […]

by

A key cannabis compound helped to reduce the number of drop seizures in patients with a severe form of epilepsy, newly published results of a clinical trial suggest. The study, published Wednesday in The Lancet, suggests that cannabidiol, alongside other anti-epilepsy treatments, reduced drop seizures in those who suffer from Lennox-Gastaut syndrome. Drop seizures involve […]

by

OTTAWA, ONTARIO–(Marketwired – Jan. 16, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its […]

by

OTTAWA, ONTARIO–(Marketwired – Jan. 16, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its […]

by

OTTAWA, ONTARIO–(Marketwired – Jan. 16, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its […]

by

PHOENIX, Dec. 19, 2017 (GLOBE NEWSWIRE) — Can a synthetic formulation of cannabidiol (CBD), one of the main molecules in cannabis, safely help control treatment-resistant “staring†… read more at: http://markets.businessinsider.com/news/stocks/INSYS-Therapeutics-Initiates-Phase-2-Clinical-Trial-of-Cannabidiol-CBD-Oral-Solution-for-Treatment-of-Refractory-Childhood-Absence-Epilepsy-in-Pediatric-PatientsProof-of-concept-study-aims-to-1011641158

by